- Home
- » Tags
- » MTOR inhibitors
Top View
- Mtor Signaling in Cancer and Mtor Inhibitors in Solid Tumor Targeting Therapy
- Mtor-Specific Inhibitors in BRAF-Mutant Melanoma Cells Counteracted by Dual Pathway Blockade
- Mtor Signaling, Function, Novel Inhibitors, and Therapeutic Targets
- Resveratrol Overcomes Cellular Resistance to Vemurafenib Through Dephosphorylation of AKT in BRAF-Mutated Melanoma Cells
- Mtor Inhibitors: a Novel Class of Anti-Cancer Agents Haris Riaz1,2, Talha Riaz1 and Syed a Hussain3*
- Downloaded from the Cbio Portal (
- Rapalogs in Viral Cancers
- Successful Treatment of Juvenile Polyposis of Infancy with Sirolimus Veronica B
- Adaptation to Mtor Kinase Inhibitors by Amplification of Eif4e To
- CDK4/6 Inhibitors: What Is the Best Cocktail?
- Figure S1. the PI3K/AKT/Mtor Pathway Activation Leads to Cell Growth
- Mtor and HDAC Inhibitors Converge on the TXNIP/Thioredoxin Pathway to Cause Catastrophic Oxidative Stress and Regression of RAS-Driven Tumors
- Protein Kinase G-Iα Hyperactivation and VASP Phosphorylation in Promoting Ovarian Cancer Cell Migration and Platinum Resistance
- Cyclin-Dependent Kinase 4 and 6 Inhibitors in Cell Cycle Dysregulation for Breast Cancer Treatment
- Nab-Rapamycin) for Surgically-Refractory Epilepsy (Rasure)
- (12) United States Patent (10) Patent No.: US 9.249,466 B2 Yu Et Al
- Sirolimus Induces Apoptosis and Reverses Multidrug Resistance in Human Osteosarcoma Cells in Vitro Via Increasing Microrna-34B Expression
- Torisel, INN-Temsirolimus
- Current Development of Mtor Inhibitors As Anticancer Agents
- Combining Mtor Inhibitors and T Cell-Based Immunotherapies in Cancer Treatment
- Clinical Outcomes After Switch to Mtor Inhibitors in Kidney
- A Combination of Temsirolimus, an Allosteric Mtor Inhibitor, with Clofarabine As a New Therapeutic Option for Patients with Acute Myeloid Leukemia
- Multiplex Patient-Based Drug Response Assay in Pancreatic Ductal Adenocarcinoma
- A Phase I Dose-Escalation Study of the BRAF Inhibitor Vemurafenib in Combination with the MTOR Inhibitor Everolimus in Subjects with Advanced Cancer
- Mtor Kinase Inhibitors Promote Antibody Class Switching Via
- The Evolving Role of Mtor Inhibition in Transplantation Tolerance
- Sequential Or Concomitant Inhibition of Cyclin-Dependent Kinase 4/6
- Genetic and Pharmacologic Evidence That Mtor Targeting Outweighs Mtorc1 Inhibition As an Antimyeloma Strategy
- Marine-Derived Natural Products As ATP-Competitive Mtor Kinase Inhibitors for Cancer Therapeutics
- 1 Mtorc1 Inhibition Induces Resistance To
- Leu2010170.Pdf
- Mtor and HDAC Inhibitors Converge on the TXNIP/Thioredoxin Pathway to Cause
- Dual Mtor/PI3K Inhibition Limits PI3K-Dependent Pathways
- Mtorc1 Inhibition Induces Resistance to Methotrexate and 6-Mercaptopurine in Phþ and Ph-Like B-ALL Thanh-Trang T
- Chemotactic Activation of Dictyostelium AGC-Family Kinases AKT and PKBR1 Requires Separate but Coordinated Functions of PDK1 and TORC2
- Administration of Mtor Inhibitors
- Mtor Signaling in Kidney Diseases
- Immunosuppressive Drugs and Fertility
- Treatment of Advanced Thyroid Cancer with Targeted Therapies: Ten Years of Experience
- Fulltextthesis.Pdf
- Mtorc1/2 Inhibition Preserves Ovarian Function and Fertility During Genotoxic Chemotherapy
- Role of Chemotherapy, VEGFR Inhibitors and Mtor Inhibitors in Advanced Perivascular Epithelioid Cell Tumours (Pecomas)
- Mtor Inhibition Activates Overall Protein Degradation by the Ubiquitin Proteasome System As Well As by Autophagy